Teva names acting CFO; FDA warns on Lovenox safety; Forest wraps more Bystolic suits;

@FiercePharma: Biggest new news online: Will Merck be next to join Big Pharma's asset sale parade? Story | Follow @FiercePharma

@CarlyHFierce: Does the Justice Department's off-label marketing enforcement actually deter bad behavior? With GSK, maybe. More | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) tapped Kobi Altman to serve as acting CFO after Eyal Desheh stepped up from that role to be interim CEO while the company searches for a replacement for Jeremy Levin. Report

> The FDA issued a new warning on Sanofi's ($SNY) blood thinner Lovenox and its generic copies, asking doctors to be careful inserting and removing spinal catheters in patients using it. Report

> Forest Laboratories ($FRX) wrapped up the last of its patent litigation over the blood pressure drug Bystolic, with a deal allowing Actavis ($ACT) and several other generics makers to sell their copies three months before a 2021 patent expires. Release

> Experts say broader criteria for diagnosing ADHD could lead to overtreatment in the U.S. to the tune of $500 million a year. Report

> The hedge fund Elliott International has built up a stake of almost 12% in the German drug distributor Celesio, which U.S.-based rival McKesson ($MCK) is seeking to buy for $8.3 billion. Report

Medical Device News

@FierceMedDev: ICYMI: Roche's Ventana to concoct companion Dx tests for Incyte's cancer drugs. More | Follow @FierceMedDev

@MarkHFierce: Biocept becomes the latest Dx company to outline its IPO terms - full speed ahead. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Gold nanoparticles first to deliver RNA to brain tumors. More from FierceDrugDelivery | Follow @MichaelGFierce

> Surefire bags $18.2M for cancer-treating catheters. More

> Bacterin turns to distributor for European expansion. Item

> Investors elated over HeartWare's stellar Q3 heart pump sales. Article

> Medtronic wins FDA nod to use software with competitors' tech. Story

Biotech News

@FierceBiotech: Novartis R&D will ax 500 staffers, boost Boston in global realignment. More | Follow @FierceBiotech

@JohnCFierce: Geron shares double on imetelstat data. Quite a reversal of fortune for Geron. Story | Follow @JohnCFierce

@DamianFierce: Medtronic wins FDA approval to use its software with competitors' tech. More | Follow @DamianFierce

@EmilyMFierce: Next Generation: Cancer Drug in Disguise. Article | Follow @EmilyMFierce

> Shire slashes R&D ops, refocuses pipeline as it restructures in Europe, U.S. News

> GlaxoSmithKline toes the line in Breo launch. Item

Pharma Manufacturing News

> Hospira CEO looks to better days as 'swamp draining' nears end. News

> Wholesaler McKesson settles another price-manipulation suit. Article

> FDA finally lifts warning letter on AMRI fill/finish facility. More

> Visa woes still stalling FDA plans for China inspections. Story

> Pfizer contractors testing new methods to clean up old production site. News

> Nosco hiring 51 staff for packaging and labeling plant. Item

Vaccines News

> Merck readies FDA submission for son of Gardasil. News

> Takeda, Boehringer invest to move CMV vaccine into clinic. Story

> European scientists join Sanofi, Pfizer in C. diff vaccine race. Article

> Study finds one HPV vaccine dose gives strong, durable immune response. News

> WHO massively scales up Middle East polio immunization plan. Story

> Shipping snafu prompts Navy review of vaccination procedures. Item

And Finally... The FDA proposes to all but eliminate artery-clogging trans fats in foods. Report (sub. req.)

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.